# LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

> **NCT04752722** · PHASE1,PHASE2 · RECRUITING · sponsor: **enGene, Inc.** · enrollment: 350 (estimated)

## Conditions studied

- Superficial Bladder Cancer
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

## Interventions

- **DRUG:** EG-70 (phase 1)
- **DRUG:** EG-70 (phase 2)

## Key facts

- **NCT ID:** NCT04752722
- **Lead sponsor:** enGene, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-22
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04752722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04752722, "LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04752722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*